Epstein-Barr virus (EBV) replication proteins are transported into the nucleus to 26 synthesize viral genomes. We here report molecular mechanisms for nuclear transport of EBV 27 DNA polymerase. The EBV DNA polymerase catalytic subunit, BALF5, was found to 28 accumulate in the cytoplasm when expressed alone, while the EBV DNA polymerase 29 processivity factor, BMRF1, moved into nucleus by itself. Co-expression of both proteins, 30 however, resulted in efficient nuclear transport of BALF5. Deletion of nuclear localization 31 signal of BMRF1 diminished their nuclear transport, although both proteins can still interact. 32
2

Summary 25
Epstein-Barr virus (EBV) replication proteins are transported into the nucleus to 26 synthesize viral genomes. We here report molecular mechanisms for nuclear transport of EBV 27 DNA polymerase. The EBV DNA polymerase catalytic subunit, BALF5, was found to 28 accumulate in the cytoplasm when expressed alone, while the EBV DNA polymerase 29 processivity factor, BMRF1, moved into nucleus by itself. Co-expression of both proteins, 30 however, resulted in efficient nuclear transport of BALF5. Deletion of nuclear localization 31 signal of BMRF1 diminished their nuclear transport, although both proteins can still interact. 32
These results suggest that BALF5 interacts with BMRF1 to effect transport into the nucleus. 33
Interestingly, we found that Hsp90 inhibitors or knockdown of Hsp90β with short hairpin RNA 34 prevented the BALF5 nuclear transport even in the presence of BMRF1, both in transfection 35 assays and in the context of lytic replication. Immunoprecipitation analyses suggested that the 36 molecular chaperone Hsp90 interacts with BALF5. Treatment with Hsp90 inhibitors blocked 37 viral DNA replication almost completely during lytic infection, and knockdown of Hsp90β 38 reduced viral genome synthesis. Collectively, we speculate that Hsp90 interacts with BALF5 in 39 the cytoplasm to assist complex formation with BMRF1, leading to nuclear transport. Hsp90 40 inhibitors may be useful for the therapy for EBV associated diseases in future. 
Immunofluorescence analyses 149
HeLa cells were grown on cover slips and transfected with pcDNA-FLAG-BALF5, 150
pcDNA-BMRF1, pcDNA-BMRF1ΔC, and pcDNA-HA-Hsp90 (provided by Dr. Matsuura, 151
Osaka University). AGS-CR2/EGFP-EBV cells were grown on cover slips and transfected with 152 pcDNA-BZLF1. At 24 h post-transfection, cells were washed with ice-cold phosphate-buffered 153 saline (PBS) and fixed by 3.7% formalin for 15 min. Fixed cells were washed with PBS and 154 incubated in a blocking buffer (2.5% BSA, 0.2 M glycine, 0.1% Triton X-100, and 0.02% 155 sodiumazide in PBS) for 30 min at room temperature. The samples were then incubated with the 156 primary antibodies diluted in blocking buffer at 4°C overnight, followed by the incubation with 157 diluted secondary goat anti-rabbit, anti-rat, and anti-mouse IgG antibodies conjugated with 158 Alexa fluor 488, 594 or 688 for 30 min at RT. 159
Lytic infection-induced Tet-BZLF1/B95-8 cells were treated with ice-cold modified 160 cytoskeleton (mCSK) buffer [10 mM piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) (pH 161 6.8), 300 mM sucrose, 1 mM MgCl 2 , 1 mM EGTA, 1 mM dithiothreitol, 1 mM 162 phenylmethylsulfonyl fluoride, 0.5% Triton X-100) on ice for 10 min. Multiple protease 163 inhibitors (Sigma; 25 μl/ml), 200 μM Na3VO4, and 20 mM NaF were also added to the buffer, 164 followed by fixation with 70% ethanol at -20°C overnight. Then cells were washed with PBS 165 containing 0.1% normal goat serum and 0.01% Tween 20, permeabilized with 0.5% Triton 166 X-100 in PBS for 15 min, blocked for 1 h in 10% normal goat serum in PBS. Samples were then 167 incubated overnight with the primary antibodies diluted in PBS containing 0.1% normal goat 168 on July 14, 2017 by guest http://jvi.asm.org/ Downloaded from 8 serum and 0.01% Tween 20, followed by the incubation with diluted Alexa fluor (488 or 169 594)-conjugated secondary antibodies for 1 h. 170
All the primary antibodies were employed at a 1:100 dilution, and the secondary 171
antibodies were employed at a 1:200 dilution. All washes after antibody incubation were 172 performed with PBS containing 0.1% normal goat serum and 0.01% Tween 20. Both samples 173
were mounted in ProLong Gold antifade reagent with 4', 6'-diamidino-2-phenylindole (DAPI) 174 (Molecular Probes) and analyzed by laser scanning confocal microscopy (Carl Zeiss 175
MicroImaging,
Inc.). Images were captured with a plan-Apochromat 176 100×/1.4-numericalaperture oil immersion objective and processed using an LSM510 Meta 177
microscope. 178 179
Immunoprecipitation analyses 180
HEK293T cells in 6cm dishes were transfected with pcDNA-FLAG-BALF5, 181 pcDNA-BMRF1, and pcDNA-HA-Hsp90 and cultivated for 24 hours. The cells were harvested, 182 washed with cold PBS, and then lysed for 10 min on ice with 500 μl of ice-cold mCSK buffer 183 containing 0.1% Triton X-100, 50mM NaCl, and 25 μl/ml multiple protease inhibitors. When 184 BMRF1 was expressed, the samples were treated with DNase I (1,000 units/ml) for 30 min at 185 25°C to solubilize BMRF1. After treatment, homogenates were centrifuged at 3,000 × g at 4°C 186
for 5 min. The supernatant fraction was used as extracts for assays. Hundred microliters each of 187 Triton X-100-extractable fractions were diluted with mCSK buffer to 500 μl, and then mixed 188 with 1 μg each of anti-HA, anti-BALF5, or anti-BMRF1 antibodies, or 10 μl anti-M2 beads 189 
246
Nuclear transfer of the BALF5 DNA polymerase catalytic subunit is dependent on the 247 BMRF1 polymerase processivity factor. 248
All EBV DNA replication proteins localize to nuclei of lytic replication-induced cells. 249
However, the nuclear localization of BBLF2/3 and BSLF1 proteins, constituting the viral 250 helicase-primase complex, requires the concurrent presence of BBLF4 protein (17). Therefore, 251
we first examined localization of the BALF5 DNA polymerase catalytic subunit in HeLa cells 252 transfected with FLAG-tagged BALF5 and/or BMRF1 expression vectors, using 253 immunofluorescence staining. As shown in Fig. 1A , when FLAG-BALF5 was expressed alone, 254 it was detected predominantly in the cytoplasm. In contrast, BMRF1 was observed exclusively 255 in the nucleus (Fig. 1B) . When both proteins were co-expressed, BALF5 efficiently localized to 256 the nucleus (Fig. 1C) . It is known that the BMRF1 protein interacts with the BALF5 polymerase 257 catalytic subunit to form a heterodimer complex, resulting in acquirement of enhanced 258 polymerase processivity and exonuclease activities (41, 43). Co-immunoprecipitation assay 259 confirmed that BALF5 interacted with BMRF1 (Fig. 1D) . These results clearly indicate that 260 BALF5 by itself cannot translocate to the nucleus, but it can do so in a BMRF1 dependent 261
manner. 262
It is known that BMRF1 protein possesses a nuclear localization signal (NLS) in its 263 C-terminal domain ( Fig. 2A) processivity factor in vitro, just like wild-type BMRF1 (30). Expectedly, unlike wild-type 266 BMRF1, BMRF1ΔC was detected in the cytoplasm (Fig. 2B) . This truncated mutant could also 267 physically interact with BALF5 (Fig. 2C) . When BMRF1ΔC mutant and BALF5 were 268 co-expressed, BALF5 remained in the cytoplasm. (Fig. 2D) , suggesting that BALF5 utilizes the 269 NLS function of BMRF1 for its transport into the nucleus. 270 271
Hsp90 inhibitors prevent BMRF1-dependent nuclear transport of the BALF5 protein. 272
Hsp90 is known to facilitate conformational maturation, stabilization, protein 273 interaction, and intracellular trafficking of many client proteins. It was reported that Hsp90 was 274 involved in nuclear translocation of UL-30, a DNA polymerase catalytic subunit of HSV-1 (7). 275 Therefore, we examined the possibility that it might be involved in the nuclear transport of 276 BALF5 and BMRF1 proteins. In the presence or absence of an Hsp90 inhibitor, Radicicol, 277 BALF5 was detected in the cytoplasm when the protein was expressed alone (Fig. 3A) , while 278 BMRF1 was found in the nucleus (Fig. 3B ), indicating at least that nuclear transport of the 279 BMRF1 protein is independent of Hsp90. When both proteins were co-expressed, 280 BMRF1-dependent nuclear transport of BALF5 was clearly inhibited by Radicicol (Fig. 3C) . 281 Figure 3D shows a numerical analysis of the intracellular localization patterns of BALF5. In the 282 absence of Hsp90 inhibitors, BALF5 was predominantly localized in nucleus in almost all the 283 cells expressing both proteins (Fig.3D) . In the presence of Radicicol or 17-AAG, cell 284 populations localizing in cytoplasm increased vastly. Thus, BALF5 nuclear localization is 285 absolutely dependent on BMRF1 and blocked by Hsp90 inhibitors. It should be noted that the 286 expressed Hsp90 was localized predominantly in cytoplasm in all the cases. that the level of Chk1 was greatly decreased by Radicicol treatment (Fig. 3E) , confirming that 291 the inhibitor was working efficiently in this system. From these results, we speculate that Hsp90 292 is involved in the association between the BALF5 and BMRF1 proteins in the cytoplasm. BALF5 exhibited cytoplasmic localization (Fig. 4A) . Accordingly, replication compartments 302 diminished, and BMRF1 was distributed throughout nuclei (Fig. 4B) . Thus, Hsp90 inhibitors 303 prevented nuclear localization of the BALF5 protein not only in an overexpression system but 304 also in the context of cells featuring lytically-replicating viruses. 305
306
BALF5 is a possible client protein of Hsp90. 307
To validate our findings, 293T cells were transfected with combinations of HA 308 tagged-Hsp90, FLAG-tagged-BALF5 and BMRF1 expression vectors in the absence or 309 presence of Hsp90 inhibitor, Radicicol, and protein-protein interactions were examined by 310 immunoprecipitation analysis (Fig.5 ). Cells were extracted with 0.1% TritonX-100 mCSK 311 buffer containing 50 mM NaCl (and treated with DNase I only when BMRF1 was expressed), 312 FLAG-BALF5, anti-HA antibodies could co-immunoprecipitate FLAG-BALF5 protein (Fig. 5A,  315 lane 11). Conversely, anti-FLAG antibodies could co-immunoprecipitate the HA-Hsp90 protein 316 (Fig. 5A, lane 12) . Although the interaction between FLAG-BALF5 and HA-Hsp90 was fairly 317 weak (Fig. 5A) , it is known that interactions of Hsp90 and client proteins are generally not so 318 strong as to be detected easily by immunoprecipitation analysis. The interaction was diminished 319
by Radicicol treatment (Fig. 5B , compare lanes 3-4 with lanes 7-8), supporting the idea that 320
Hsp90 and BALF5 interact with each other. The amount of BALF5 protein did not change by 321
Hsp90 treatment, while the amount of cdc2 protein, a host Hsp90 client protein, was decreased 322 (Fig. 5C ). This result indicates that the diminished interaction between Hsp90 and BALF5 is not 323 due to the reduction of BALF5 protein. We further examined immunoprecipitation analysis in 324 the presence of molybdate to confirm the interaction between BALF5 and Hsp90. It is known 325 that molybdate stabilizes the interaction of Hsp90 and its client proteins (10, 35). The 326 Hsp90/BALF5 interaction was significantly stabilized in the presence of molybdate (Fig. 5D , 327 compare lane 3 with lane 6). In contrast, when HA-Hsp90 and BMRF1 were co-expressed, 328 BMRF1 did not co-immunoprecipitate with Hsp90 (Fig. 5E, lane 3) , and vice versa (Fig. 5E,  329 lane 4). Any association between BMRF1 and Hsp90 was not detected even in the presence of 330 molybdate (Fig. 5E, lanes 7-8) . Taken together, the results indicate that BALF5, but not BMRF1, 331 is a possible client protein of Hsp90. 332 333 Hsp90 assists complex formation between the BALF5 and BMRF1 proteins. 334
Next, we examined whether Hsp90 is included in the BALF5 and BMRF1 complex. 335
When three factors were overexpressed, protein-to-protein interactions of BALF5 and BMRF1 336 on July 14, 2017 by guest http://jvi.asm.org/ Downloaded from proteins could be clearly demonstrated by immunoprecipitation, using each antibody (Fig. 5F , 337 lanes 4-5). However, association of Hsp90 with the BALF5-BMRF1 complex could barely be 338 detected (Fig. 5F, lane 3) , suggesting that Hsp90 is absent in the BALF5-BMRF1 complex. 339
Radicicol treatment attenuated the BALF5-BMRF1 association (Fig. 5F, lanes 9 and 10) . 340
Considering these observations, we speculate that Hsp90 interacts at least with BALF5 protein 341 to facilitate BALF5-BMRF1 complex formation. 342 343
Hsp90 inhibition suppresses EBV DNA replication. 344
Because Hsp90 inhibitors changed localization of EBV DNA polymerase catalytic 345 subunit, we speculated that such treatment might suppress EBV DNA replication. With 346 quantitative real-time PCR, levels of viral DNA increased with time ( Fig. 6A closed squares) in 347 lytic replication-induced B95-8 cells. Treatment of cells with 1 μM Radicicol almost completely 348 blocked viral genome synthesis at each time point (Fig. 6A closed triangles) . Similar effects 349
were observed when cells were treated with another Hsp90 inhibitor, 17-AAG (data not shown). 350
Importantly, Hsp90 inhibitor did not affect the expression level of BZLF1 (Fig. 6B) . 351
Furthermore, Hsp90 inhibitor did not affect cell viability (Fig. 6C) , although the induction of lytic 352 replication resulted in complete growth arrest (Fig. 6D) Hsp90α is not induced during EBV lytic infection, we focused on the effect of Hsp90β 362 knockdown. The Hsp90β expression level was significantly reduced in shHsp90β-transduced 363
AGS-CR2/EGFP-EBV cells harboring recombinant EBV genomes, compared to that in 364
shLuc-transduced cells (Fig. 7A) . When lytic replication was induced in shLuc-transduced cells 365
by BZLF1 transfection as a positive control, the level of EBV DNA markedly increased (more 366 than 40-fold) (Fig. 7B, shLuc+BZLF1) . In contrast, when lytic replication was induced in 367 shHsp90β-transduced cells, the increase of viral DNA synthesis was far less than that of 368 BZLF1-transfected shLuc-transduced cells (Fig. 7B) . Thus, knockdown of Hsp90β prevented 369 EBV DNA replication. 370 371
Knockdown of Hsp90β prevents BMRF1-dependent nuclear translocalization of BALF5. 372
Next, the effects of Hsp90β knockdown on localization of BALF5 and BMRF1 373 proteins were examined. When lytic replication was induced in shLuc-transduced 374 AGS-CR2/EGFP-EBV cells by BZLF1 transfection, both BALF5 and BMRF1 proteins were 375 accumulated in the nucleus (Fig. 8A-a) . On the other hand, in the shHsp90β-transduced 376 AGS-CR2/EGFP-EBV cells, BALF5 protein remained in the cytoplasm (Fig. 8A-b) . We also 377 observed the localization of both proteins on the overexpressed system in Hsp90β-knockdown 378
HeLa cells. The Hsp90β expression level was significantly reduced in shHsp90β-transduced 379
HeLa cells, compared to that in shLuc-transduced cells (Fig. 8B-c) . In the shLuc-transduced 380 cells expressing both proteins, BALF5 efficiently localized to the nucleus as well as BMRF1 381 (Fig. 8B-a) . Hsp90β mainly localized in the cytoplasm. By contrast, even in the presence of 382 BMRF1, BALF5 localized to the cytoplasm in shHsp90β-transduced cells (Fig. 8B-b The present investigation of mechanisms of nuclear transport of the EBV DNA 389 polymerase catalytic subunit, BALF5, demonstrated a dependence on BMRF1 polymerase 390 processivity factor and molecular chaperon Hsp90. 391
It is well known that DNA polymerase processivity factors of many human 392 herpesviruses such as UL-42 of herpes simplex virus type 1 (HSV-1) (18), BMRF1 of EBV (23), 393 UL-44 of human cytomegalovirus (HCMV) (33), PF-8 of Kaposi's sarcoma-associated 394 herpesvirus (KSHV) (8), p41 of human herpesvirus 6 (HHV-6) (1), and U27 of human 395 herpesvirus 7 (HHV-7) (37) localize to the nucleus when expressed alone. Processivity factors 396 other than p41 of HHV-6 have been shown to contain a functional NLS (2, 3, 8, 37, 48) . Indeed, 397
we observed that BMRF1 protein, when it was expressed alone, localized to the nucleus (Fig.  398   1B) , while C-terminal truncated BMRF1 lacking NLS did not (Fig.2B) . On the other hand, 399 nuclear transport mechanisms of DNA polymerase catalytic subunits differ among herpesviruses. 400
In the case of HSV-1 DNA polymerase (UL-30), it was previously reported that UL30 possesses 401 an NLS and can by itself be transferred to nucleus even in the absence of UL42 polymerase 402 processivity factor (4, 7, 27) . Also, HCMV DNA polymerase catalytic subunit (UL-54) 403 possesses an NLS in C-terminal domain and can itself move to the nucleus (27). Unlike HSV-1 404 UL30 and HCMV UL-54, the Pol-8 of KSHV DNA polymerase catalytic subunit alone remains 405 localized in cytoplasm and translocates to the nucleus with the help of PF-8 polymerase 406 processivity factor, although involvement of Hsp90 on their association has not been clarified 407 it has become apparent that there are several critical differences regarding the nuclear 415 translocation mechanisms of the DNA polymerase of EBV (BALF5) and that of HSV-1 (UL-30). 416
First, UL-30 has its own NLS and by itself translocates to nuclei, while BALF5 does not have 417 one. Second, UL-30 appeared to interact with Hsp90 and get stabilized. This is because the 418 addition of proteasome inhibitor, MG132, antagonized the destabilization of UL-30 caused by 419 Hsp90 inhibitors (7). By contrast, MG132 treatment did not affect the level of BALF5 in the 420 presence of Hsp90 inhibitors (data not shown). Thus, it appears that Hsp90 is involved in both 421 trafficking and stabilization of HSV-1 UL30, while Hsp90 is not involved in stabilization of 422 EBV BALF5. Rather, Hsp90 inhibitor, Radicicol, prevented the complex formation between 423 BALF5 and BMRF1 (Fig. 5F ). Thus, Hsp90 promotes the association of BALF5 with BMRF1, 424 and consequently BALF5 translocates to nuclei. 425
Immunoprecipitation analyses demonstrated that BALF5 interacted with Hsp90, and 426 that the BALF5-BMRF1 complex, however, did not contain Hsp90 (Fig. 5D) . It is reported that 427 aryl hydrocarbon receptor (AhR) interacts with Hsp90 for its stabilization and heterodimerizes 428 with the AhR nuclear translocator (Arnt), resulting in dissociation of Hsp90 (19). Molecular 429 chaperones such as Hsp90 were originally thought to mediate the post-translational assembly of 430 protein complexes, without becoming actual components of complexes (14) . From this point of 431 view, since Hsp90 was not detected at all in the BALF5-BMRF1 complex, it is possible that 432 on July 14, 2017 by guest http://jvi.asm.org/ Downloaded from
